Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Antares Pharma","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"$5.0 million","newsHeadline":"Antares Pharma Enters Exclusive License Agreement With Ferring Pharmaceuticals for Nocdurna\u00ae in U.S.","therapeuticArea":"Urology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Urology","graph2":"Approved"},{"orgOrder":0,"company":"Serenity LLC","sponsor":"Acerus Pharmaceuticals","pharmaFlowCategory":"D","amount":"$16.0 million","upfrontCash":"$6.0 million","newsHeadline":"Acerus Announces Definitive Agreement to Acquire Serenity LLC and The Global Rights To NOCTIVA\u2122","therapeuticArea":"Urology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"February 2022","url1":"","url2":"","graph1":"Urology","graph2":"Approved"},{"orgOrder":0,"company":"Serenity Pharmaceuticals","sponsor":"Acerus Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Acerus Announces Closing of Acquisition of Serenity Pharmaceuticals LLC and Acquisition of Global Rights to Noctiva","therapeuticArea":"Urology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Urology","graph2":"Approved"},{"orgOrder":0,"company":"Avenacy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avenacy Announces Launch of Desmopressin Acetate for Injection in the U.S. Market","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2024","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals for Desmopressin Acetate

    Menu

    Desmopressin Acetate

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    DOSSIERs // Finished Dosage Forms

    DRUG PRODUCT COMPOSITION

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    REF. STANDARDS & IMPURITIES

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Avenacy

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Avenacy Announces Launch of Desmopressin Acetate for Injection in the U.S. Market

              Details:

              The company launched desmopressin acetate for injection in the United States as a therapeutic equivalent generic for DDAVP for treating is multi-indicated for patients with central diabetes insipidus, hemophilia A, and von willebrand’s disease (Type I).

              Lead Product(s): Desmopressin Acetate

              Therapeutic Area: Rare Diseases and Disorders Product Name: DDAVP-Generic

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 15, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Serenity Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Country
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Acerus Announces Closing of Acquisition of Serenity Pharmaceuticals LLC and Acquisition of Global Rights to Noctiva

              Details:

              Noctiva is indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to void. It is the first FDA-approved therapy for nocturia.

              Lead Product(s): Desmopressin Acetate

              Therapeutic Area: Urology Product Name: Noctiva

              Highest Development Status: Approved Product Type: Peptide

              Partner/Sponsor/Collaborator: Acerus Pharmaceuticals

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Acquisition March 09, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Serenity LLC

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Country
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Acerus Announces Definitive Agreement to Acquire Serenity LLC and The Global Rights To NOCTIVA™

              Details:

              Both Noctiva™ and Natesto® are highly clinically differentiated products with significant patent protection into the 2030s, that Acerus management feels could reach double-digit market share in each of these large market opportunities.

              Lead Product(s): Desmopressin Acetate

              Therapeutic Area: Urology Product Name: Noctiva

              Highest Development Status: Approved Product Type: Peptide

              Partner/Sponsor/Collaborator: Acerus Pharmaceuticals

              Deal Size: $16.0 million Upfront Cash: $6.0 million

              Deal Type: Agreement February 28, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Ferring Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Switzerland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Antares Pharma Enters Exclusive License Agreement With Ferring Pharmaceuticals for Nocdurna® in U.S.

              Details:

              This license agreement for NOCDURNA expands Antares Pharma's urology portfolio, which already includes XYOSTED, the best-selling branded testosterone replacement product in the United States.

              Lead Product(s): Desmopressin Acetate

              Therapeutic Area: Urology Product Name: Nocdurna

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: Antares Pharma

              Deal Size: $25.0 million Upfront Cash: $5.0 million

              Deal Type: Licensing Agreement October 01, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY